← Russell 3000 cross-section

INDV Indivior Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$4.2bn
Revenue TTM
$1.3bn
Net income TTM
$356m
Free cash flow
$-111m
Composite score
61.0
Sector rank
#1194

Valuation

P / E
11.9
EV / EBITDA
10.4
EV / sales
3.4
FCF yield
-2.63%
Earnings yield vs 10-yr
3.70pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
26.8%
EBITDA margin
32.3%
ROE
-171.2%
ROIC
738.6%
Revenue growth

Insider activity, last 90 days

Net open-market
$-2.72m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Substantially all of our net revenue was derived from sales of SUBLOCADE and other buprenorphine-based sublingual products (including SUBOXONE Film, SUBOXONE Tablet and SUBUTEX Tablet). SUBLOCADE accounted for 74% and 74% of our net revenue for the three and six months ended June 30, 2026, respectively, and 69% and 68% for the three and six months ended June 30, 2025, respectively. Other buprenorphine-based sublingual products accounted for 25% and 25% of our net revenue for the three and six months ended June 30, 2026 and 27% and 29% of our net revenue for the three and six months ended June 30, 2025, respectively. Commitments and Contingencies. …Indivior Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →